Literature DB >> 10608759

Partial "repair" of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection.

S Carl1, R Daniels, A J Iafrate, P Easterbrook, T C Greenough, J Skowronski, F Kirchhoff.   

Abstract

A 36-bp deletion close to the 5' end of NEF that impaired Nef function was found in a long-term nonprogressor with human immunodeficiency virus type 1 (HIV-1) infection. Forms containing an adjacent duplication of 33 bp were also frequently observed. The duplication showed no homology to the deleted region but restored the overall length of the first variable loop of Nef. NEF alleles carrying the duplication were active in class I major histocompatibility complex (MHC-I) down-modulation and enhancement of virus infectivity. However, they showed little activity in CD4 down-regulation and were unable to stimulate viral replication in human peripheral blood mononuclear cells. Our study indicates that the enhancement of virion infectivity and the stimulation of HIV-1 replication in lymphocytes are distinct functions of Nef. Our findings also illustrate the capacity for repair of attenuating deletions in HIV-1 infection and suggest that a selective pressure for Nef-mediated MHC-I down-modulation and/or enhancement of virion infectivity exists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10608759     DOI: 10.1086/315187

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Authors:  Hendrik Huthoff; Atze T Das; Monique Vink; Bep Klaver; Fokla Zorgdrager; Marion Cornelissen; Ben Berkhout
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

3.  Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection.

Authors:  Steffen Wildum; Michael Schindler; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Authors:  S Carl; T C Greenough; M Krumbiegel; M Greenberg; J Skowronski; J L Sullivan; F Kirchhoff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo.

Authors:  S Glushakova; J Münch; S Carl; T C Greenough; J L Sullivan; L Margolis; F Kirchhoff
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progression.

Authors:  Ravindra Pushker; Jean-Marc Jacqué; Denis C Shields
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

7.  Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism.

Authors:  Armin Papkalla; Jan Münch; Claas Otto; Frank Kirchhoff
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Authors:  Andreas Jekle; Birgit Schramm; Prerana Jayakumar; Verena Trautner; Dominique Schols; Erik De Clercq; John Mills; Suzanne M Crowe; Mark A Goldsmith
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Authors:  Erin E Verity; Dimitra Zotos; Kim Wilson; Catherine Chatfield; Victoria A Lawson; Dominic E Dwyer; Anthony Cunningham; Jennifer Learmont; Wayne Dyer; John Sullivan; Melissa Churchill; Steven L Wesselingh; Dana Gabuzda; Paul R Gorry; Dale A McPhee
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.

Authors:  Raghavan Chinnadurai; Devi Rajan; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.